CHEMBL1163

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:ATCCode gptkb:C07AB03
gptkbp:bioavailability 50% (oral)
gptkbp:CASNumber gptkb:29122-68-7
gptkbp:color white (solid)
gptkbp:contraindication asthma
severe bradycardia
second- or third-degree heart block
gptkbp:drugClass beta blocker
gptkbp:eliminationHalfLife 6-7 hours
gptkbp:excretion renal
gptkbp:hasInChIKey METKIMKYRPQLGS-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C14H22N2O3
gptkbp:hasSMILES CC(C)NCC(CO)OC1=CC=C(C=C1)CC(=O)N
gptkbp:hasTherapeuticUse antianginal agent
antihypertensive agent
gptkbp:hasUNII 50VV3VW0TI
gptkbp:hasWikipediaPage gptkb:Atenolol
gptkbp:hasYearOfFirstApproval 1976
https://www.w3.org/2000/01/rdf-schema#label CHEMBL1163
gptkbp:indication gptkb:arrhythmia
myocardial infarction
hypertension
angina pectoris
gptkbp:isApprovedDrug true
gptkbp:IUPACName 4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenylacetamide
gptkbp:KEGGID gptkb:D00222
gptkbp:legalStatus prescription only
off-patent
gptkbp:listedOn gptkb:WHO_Model_List_of_Essential_Medicines
gptkbp:manufacturer gptkb:AstraZeneca
gptkbp:MeSH_ID D000889
gptkbp:metabolism minimal hepatic metabolism
gptkbp:molecularWeight 266.34
gptkbp:name gptkb:Atenolol
gptkbp:pregnancyCategory C (US)
gptkbp:PubChem_CID gptkb:CHEMBL1163
2162
DB00335
CHEBI:2904
gptkbp:routeOfAdministration oral
gptkbp:sideEffect dizziness
fatigue
bradycardia
cold extremities
gptkbp:synonym gptkb:Atenololum
gptkb:Tenormin
Atenolol hydrochloride
gptkbp:target beta-1 adrenergic receptor
gptkbp:bfsParent gptkb:Selegiline
gptkbp:bfsLayer 7